Nanoparticles as multifunctional devices for the topical treatment of cutaneous leishmaniasis

Expert Opinion on Drug Delivery

Volumn 11, Issue 4, 2014, Pages 579-597

  Moreno, Esther ^a   Schwartz, Juana ^a   Fernández, Celia ^a   Sanmartín, Carmen ^a   Nguewa, Paul ^a   Irache, Juan Manuel ^a   Espuelas, Socorro ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Cutaneous leishmaniasis; Dermal retention; Immunostimulation; Nanoparticles; Nitric oxide; Photodynamic therapy; Silver nanoparticles; Topical treatment

Indexed keywords

ANTILEISHMANIAL AGENT; NANOPARTICLE; NITRIC OXIDE; POLYPEPTIDE ANTIBIOTIC AGENT; SILVER NANOPARTICLE;

AMASTIGOTE; ANTIPROTOZOAL ACTIVITY; CHEMOTHERAPY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; LOCAL THERAPY; NANOTECHNOLOGY; NONHUMAN; PHOTODYNAMIC THERAPY; PHYSICAL CHEMISTRY; REVIEW; SKIN LEISHMANIASIS; SKIN PENETRATION; SKIN PERMEABILITY; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE PREPARATION; SYMBIOSIS; TOPICAL TREATMENT; WOUND HEALING;

ADMINISTRATION, CUTANEOUS; ANTIPROTOZOAL AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LEISHMANIASIS, CUTANEOUS; NANOPARTICLES; SKIN ABSORPTION;

EID: 84897825559     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.885500     Document Type: Review

References (160)

1. Kaye P, Scott P. Leishmaniasis: complexity at the host-pathogen interface. Nat Rev Microbiol 2011;9(8):604-15
2. McGwire BS, Satoskar AR. Leishmaniasis: clinical syndromes and treatment. QJM 2014;107(1):7-14
3. Reithinger R, Dujardin JC, Louzir H, et al. Cutaneous leishmaniasis. Lancet Infect Dis 2007;7(9):581-96
4. WHO. Control of the leishmaniasis: report of a meeting of the WHO Expert Committee on the Control of Leishmaniasis, Geneva, 22-26 March 2010. WHO technical report series 949 2010. p. 1-185
5. Sundar S, Chakravarty J. Leishmaniasis: an update of current pharmacotherapy. Expert Opin Pharmacother 2013;14(1):53-63
6. David CV, Craft N. Cutaneous and mucocutaneous leishmaniasis. Dermatol Ther 2009;22(6):491-502
7. Reveiz L, Maia-Elkhoury AN, Nicholls RS, et al. Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update. PLoS One 2013;8(4):e61843
8. Ameen M. Cutaneous leishmaniasis: advances in disease pathogenesis, diagnostics and therapeutics. Clin Exp Dermatol 2010;35(7):699-705
9. Gonzalez U, Pinart M, Reveiz L, et al. Designing and reporting clinical trials on treatments for cutaneous leishmaniasis. Clin Infect Dis 2010;51(4):409-19
10. Olliaro P, Vaillant M, Arana B, et al. Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis. PLoS Negl Trop Dis 2013;7(3):e2130
11. Gonzalez U, Pinart M, Rengifo-Pardo M, et al. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev 2009;(2):CD004834
12. Gonzalez U, Pinart M, Reveiz L, Alvar J. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev 2008;(4):CD005067
13. Kim DH, Chung HJ, Bleys J, Ghohestani RF. Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. PLoS Negl Trop Dis 2009;3(2):e381
14. Carneiro G, Aguiar MG, Fernandes AP, Ferreira LA. Drug delivery systems for the topical treatment of cutaneous leishmaniasis. Expert Opin Drug Deliv 2012;9(9):1083-97
15. Garnier T, Croft SL. Topical treatment for cutaneous leishmaniasis. Curr Opin Investig Drugs 2002;3(4):538-44
16. Akomeah FK. Topical dermatological drug delivery: quo vadis? Curr Drug Deliv 2010;7(4):283-96
17. Dancik Y, Anissimov YG, Jepps OG, Roberts MS. Convective transport of highly plasma protein bound drugs facilitates direct penetration into deep tissues after topical application. Br J Clin Pharmacol 2012;73(4):564-78
18. Forster M, Bolzinger MA, Fessi H, Briancon S. Topical delivery of cosmetics and drugs. Molecular aspects of percutaneous absorption and delivery. Eur J Dermatol 2009;19(4):309-23
19. Mantyla A, Garnier T, Rautio J, et al. Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone. J Med Chem 2004;47(1):188-95
20. Potts RO, Guy RH. Predicting skin permeability. Pharm Res 1992;9(5):663-9
21. Dorlo TP, Balasegaram M, Beijnen JH, de Vries PJ. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother 2012;67(11):2576-97
22. El-On J, Jacobs GP, Witztum E, Greenblatt CL. Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals. Antimicrob Agents Chemother 1984;26(5):745-51
23. Nylen S, Eidsmo L. Tissue damage and immunity in cutaneous leishmaniasis. Parasite Immunol 2012;34(12):551-61
24. Nielsen JB, Nielsen F, Sorensen JA. Defense against dermal exposures is only skin deep: significantly increased penetration through slightly damaged skin. Arch Dermatol Res 2007;299(9):423-31
25. Chiang A, Tudela E, Maibach HI. Percutaneous absorption in diseased skin: an overview. J Appl Toxicol 2012;32(8):537-63
26. Gattu S, Maibach HI. Enhanced absorption through damaged skin: an overview of the in vitro human model. Skin Pharmacol Physiol 2010;23(4):171-6
27. Gattu S, Maibach HI. Modest but increased penetration through damaged skin: an overview of the in vivo human model. Skin Pharmacol Physiol 2011;24(1):2-9
28. Castro GA, Nascimento DS, Fernandes AP, et al. In vitro skin permeation of paromomycin from topical formulations across normal and stripped hairless mouse skin. STP Pharm Sci 2003;13(3):203-8
29. Ravis WR, Llanos-Cuentas A, Sosa N, et al. Pharmacokinetics and Absorption of Paromomycin and Gentamicin from Topical Creams Used to Treat Cutaneous Leishmaniasis. Antimicrob Agents Chemother 2013;57(10):4809-15
30. Ben Salah A, Ben Messaoud N, Guedri E, et al. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med 2013;368(6):524-32
31. Oshima S, Suzuki C, Yajima R, et al. The use of an artificial skin model to study transdermal absorption of drugs in inflamed skin. Biol Pharm Bull 2012;35(2):203-9
32. Garnier T, Brown MB, Lawrence MJ, Croft SL. In-vitro and in-vivo studies on a topical formulation of sitamaquine dihydrochloride for cutaneous leishmaniasis. J Pharm Pharmacol 2006;58(8):1043-54
33. Mussi SV, Fernandes AP, Ferreira LA. Comparative study of the efficacy of formulations containing fluconazole or paromomycin for topical treatment of infections by Leishmania (Leishmania) major and Leishmania (Leishmania) amazonensis. Parasitol Res 2007;100(6):1221-6
34. Bari AU. Clinical spectrum of cutaneous leishmaniasis: an overview from Pakistan. Dermatol Online J 2012;18(2):4
35. Oliveira G, Hadgraft J, Lane ME. The role of vehicle interactions on permeation of an active through model membranes and human skin. Int J Cosmet Sci 2012;34(6):536-45
36. Lane ME, Hadgraft J, Oliveira G, et al. Rational formulation design. Int J Cosmet Sci 2012;34(6):496-501
37. Fernandes AP, Carvalho FA, Tavares CA, et al. Combined interleukin-12 and topical chemotherapy for established Leishmaniasis drastically reduces tissue parasitism and relapses in susceptible mice. J Infect Dis 2001;183(11):1646-52
38. Goncalves GS, Fernandes AP, Souza RC, et al. Activity of a paromomycin hydrophilic formulation for topical treatment of infections by Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis. Acta Trop 2005;93(2):161-7
39. Ferreira LS, Ramaldes GA, Nunan EA, Ferreira LA. In vitro skin permeation and retention of paromomycin from liposomes for topical treatment of the cutaneous leishmaniasis. Drug Dev Ind Pharm 2004;30(3):289-96
40. Bavarsad N, Fazly Bazzaz BS, Khamesipour A, Jaafari MR. Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice. Acta Trop 2012;124(1):33-41
41. Carneiro G, Santos DC, Oliveira MC, et al. Topical delivery and in vivo antileishmanial activity of paromomycinloaded liposomes for treatment of cutaneous leishmaniasis. J Liposome Res 2010;20(1):16-23
42. Santos CM, de Oliveira RB, Arantes VT, et al. Amphotericin B-loaded nanocarriers for topical treatment of cutaneous leishmaniasis: development, characterization, and in vitro skin permeation studies. J Biomed Nanotechnol 2012;8(2):322-9
43. Garnier T, Mantyla A, Jarvinen T, et al. Topical buparvaquone formulations for the treatment of cutaneous leishmaniasis. J Pharm Pharmacol 2007;59(1):41-9
44. Garnier T, Mantyla A, Jarvinen T, et al. In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs. J Antimicrob Chemother 2007;60(4):802-10
45. Lecoeur H, Buffet P, Morizot G, et al. Optimization of topical therapy for Leishmania major localized cutaneous leishmaniasis using a reliable C57BL/6 Model. PLoS Negl Trop Dis 2007;1(2):e34
46. Berardesca E, Vignoli GP, Fideli D, Maibach H. Effect of occlusive dressings on the stratum corneum water holding capacity. Am J Med Sci 1992;304(1):25-8
47. Lane ME. Skin penetration enhancers. Int J Pharm 2013;447(1-2):12-21
48. Wiechers JW, Watkinson AC, Cross SE, Roberts MS. Predicting skin penetration of actives from complex cosmetic formulations: an evaluation of inter formulation and inter active effects during formulation optimization for transdermal delivery. Int J Cosmet Sci 2012;34(6):525-35
49. Gupta M, Agrawal U, Vyas SP. Nanocarrier-based topical drug delivery for the treatment of skin diseases. Expert Opin Drug Deliv 2012;9(7):783-804
50. Vardy D, Barenholz Y, Naftoliev N, et al. Efficacious topical treatment for human cutaneous leishmaniasis with ethanolic lipid amphotericin B. Trans R Soc Trop Med Hyg 2001;95(2):184-6
51. Lademann J, Richter H, Schanzer S, et al. Penetration and storage of particles in human skin: perspectives and safety aspects. Eur J Pharm Biopharm 2011;77(3):465-8
52. Labouta HI, Schneider M. Interaction of inorganic nanoparticles with the skin barrier: current status and critical review. Nanomedicine 2013;9(1):39-54
53. Marie-Alexandrine B, Stephanie B, Yves C. Nanoparticles through the skin: managing conflicting results of inorganic and organic particles in cosmetics and pharmaceutics. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2011. [Epub ahead of print]
54. Dubey V, Mishra D, Nahar M, Jain NK. Vesicles as tools for the modulation of skin permeability. Expert Opin Drug Deliv 2007;4(6):579-93
55. Benson HA. Elastic liposomes for topical and transdermal drug delivery. Methods Mol Biol 2010;605:77-86
56. Cobb SL, Denny PW. Antimicrobial peptides for leishmaniasis. Curr Opin Investig Drugs 2010;11(8):868-75
57. Marr AK, McGwire BS, McMaster WR. Modes of action of Leishmanicidal antimicrobial peptides. Future Microbiol 2012;7(9):1047-59
58. Jenssen H, Hancock RE. Therapeutic potential of HDPs as immunomodulatory agents. Methods Mol Biol 2010;618:329-47
59. Kulkarni MM, Barbi J, McMaster WR, et al. Mammalian antimicrobial peptide influences control of cutaneous Leishmania infection. Cell Microbiol 2011;13(6):913-23
60. Pinheiro da Silva F, Gallo RL, Nizet V. Differing effects of exogenous or endogenous cathelicidin on macrophage toll-like receptor signaling. Immunol Cell Biol 2009;87(6):496-500
61. Erfe MC, David CV, Huang C, et al. Efficacy of synthetic peptides RP-1 and AA-RP-1 against Leishmania species in vitro and in vivo. Antimicrob Agents Chemother 2012;56(2):658-65
62. Torrent M, Pulido D, Rivas L, Andreu D. Antimicrobial peptide action on parasites. Curr Drug Targets 2012;13(9):1138-47
63. Yount NY, Yeaman MR. Emerging themes and therapeutic prospects for anti-infective peptides. Annu Rev Pharmacol Toxicol 2012;52:337-60
64. Nakatsuji T, Gallo RL. Antimicrobial peptides: old molecules with new ideas. J Invest Dermatol 2012;132(3 Pt 2):887-95
65. Koren E, Torchilin VP. Cell-penetrating peptides: breaking through to the other side. Trends Mol Med 2012;18(7):385-93
66. Nasrollahi SA, Taghibiglou C, Azizi E, Farboud ES. Cell-penetrating peptides as a novel transdermal drug delivery system. Chem Biol Drug Des 2012;80(5):639-46
67. Splith K, Neundorf I. Antimicrobial peptides with cell-penetrating peptide properties and vice versa. Eur Biophys J 2011;40(4):387-97
68. Kim YC, Ludovice PJ, Prausnitz MR. Transdermal delivery enhanced by antimicrobial peptides. J Biomed Nanotechnol 2010;6(5):612-20
69. Kim YC, Ludovice PJ, Prausnitz MR. Transdermal delivery enhanced by magainin pore-forming peptide. J Control Release 2007;122(3):375-83
70. Lee CH, Choi HK. Effect of gramicidin on percutaneous permeation of a model drug. AAPS PharmSciTech 2000;1(2):E13
71. Urban P, Valle-Delgado JJ, Moles E, et al. Nanotools for the delivery of antimicrobial peptides. Curr Drug Targets 2012;13(9):1158-72
72. Shah PP, Desai PR, Channer D, Singh M. Enhanced skin permeation using polyarginine modified nanostructured lipid carriers. J Control Release 2012;161(3):735-45
73. Patlolla RR, Desai PR, Belay K, Singh MS. Translocation of cell penetrating peptide engrafted nanoparticles across skin layers. Biomaterials 2010;31(21):5598-607
74. Schairer DO, Chouake JS, Nosanchuk JD, Friedman AJ. The potential of nitric oxide releasing therapies as antimicrobial agents. Virulence 2012;3(3):271-9
75. Serafim RA, Primi MC, Trossini GH, Ferreira EI. Nitric oxide: state of the art in drug design. Curr Med Chem 2012;19(3):386-405
76. Horta MF, Mendes BP, Roma EH, et al. Reactive oxygen species and nitric oxide in cutaneous leishmaniasis. J Parasitol Res 2012;2012:203818
77. Englander L, Friedman A. Nitric oxide nanoparticle technology: a novel antimicrobial agent in the context of current treatment of skin and soft tissue infection. J Clin Aesthet Dermatol 2010;3(6):45-50
78. Lancaster JR Jr. Simulation of the diffusion and reaction of endogenously produced nitric oxide. Proc Natl Acad Sci USA 1994;91(17):8137-41
79. Oplander C, Muller T, Baschin M, et al. Characterization of novel nitrite-based nitric oxide generating delivery systems for topical dermal application. Nitric Oxide 2013;28:24-32
80. Han G, Zippin JH, Friedman A. From bench to bedside: the therapeutic potential of nitric oxide in dermatology. J Drugs Dermatol 2009;8(6):586-94
81. Seabra AB, de Souza GF, da Rocha LL, et al. S-nitrosoglutathione incorporated in poly(ethylene glycol) matrix: potential use for topical nitric oxide delivery. Nitric Oxide 2004;11(3):263-72
82. Seabra AB, Fitzpatrick A, Paul J, et al. Topically applied S-nitrosothiol-containing hydrogels as experimental and pharmacological nitric oxide donors in human skin. Br J Dermatol 2004;151(5):977-83
83. Mowbray M, Tan X, Wheatley PS, et al. Topically applied nitric oxide induces Tlymphocyte infiltration in human skin, but minimal inflammation. J Invest Dermatol 2008;128(2):352-60
84. Riccio DA, Schoenfisch MH. Nitric oxide release: part I. Macromolecular scaffolds. Chem Soc Rev 2012;41(10):3731-41
85. Saraiva J, Marotta-Oliveira SS, Cicillini SA, et al. Nanocarriers for nitric oxide delivery. J Drug Deliv 2011;2011:936438
86. Friedman A, Friedman J. New biomaterials for the sustained release of nitric oxide: past, present and future. Expert Opin Drug Deliv 2009;6(10):1113-22
87. Miller MR, Megson IL. Recent developments in nitric oxide donor drugs. Br J Pharmacol 2007;151(3):305-21
88. Scatena R, Bottoni P, Pontoglio A, Giardina B. Pharmacological modulation of nitric oxide release: new pharmacological perspectives, potential benefits and risks. Curr Med Chem 2010;17(1):61-73
89. Lopez-Jaramillo P, Ruano C, Rivera J, et al. Treatment of cutaneous leishmaniasis with nitric-oxide donor. Lancet 1998;351(9110):1176
90. Costa IS, de Souza GF, de Oliveira MG, Abrahamsohn ID. S-nitrosoglutathione (GSNO) is cytotoxic to intracellular amastigotes and promotes healing of topically treated Leishmania major or Leishmania braziliensis skin lesions. J Antimicrob Chemother 2013;68(11):2561-8
91. Weller RB. Nitric oxide-containing nanoparticles as an antimicrobial agent and enhancer of wound healing. J Invest Dermatol 2009;129(10):2335-7
92. Davidson RN, Yardley V, Croft SL, et al. A topical nitric oxide-generating therapy for cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 2000;94(3):319-22
93. Lopez-Jaramillo P, Rincon MY, Garcia RG, et al. A controlled, randomized-blinded clinical trial to assess the efficacy of a nitric oxide releasing patch in the treatment of cutaneous leishmaniasis by Leishmania (V.) panamensis. Am J Trop Med Hyg 2010;83(1):97-101
94. Maillard JY, Hartemann P. Silver as an antimicrobial: facts and gaps in knowledge. Crit Rev Microbiol 2013;39(4):373-83
95. Dai T, Huang YY, Sharma SK, et al. Topical antimicrobials for burn wound infections. Recent Pat Antiinfect Drug Discov 2010;5(2):124-51
96. Filon FL, D'Agostin F, Crosera M, et al. In vitro absorption of metal powders through intact and damaged human skin. Toxicol In Vitro 2009;23(4):574-9
97. Wilkinson LJ, White RJ, Chipman JK. Silver and nanoparticles of silver in wound dressings: a review of efficacy and safety. J Wound Care 2011;20(11):543-9
98. Brandt O, Mildner M, Egger AE, et al. Nanoscalic silver possesses broadspectrum antimicrobial activities and exhibits fewer toxicological side effects than silver sulfadiazine. Nanomedicine 2012;8(4):478-88
99. Rai M, Yadav A, Gade A. Silver nanoparticles as a new generation of antimicrobials. Biotechnol Adv 2009;27(1):76-83
100. Sotiriou GA, Pratsinis SE. Antibacterial activity of nanosilver ions and particles. Environ Sci Technol 2010;44(14):5649-54
101. Singh RP, Ramarao P. Cellular uptake, intracellular trafficking and cytotoxicity of silver nanoparticles. Toxicol Lett 2012;213(2):249-59
102. Yen HJ, Hsu SH, Tsai CL. Cytotoxicity and immunological response of gold and silver nanoparticles of different sizes. Small 2009;5(13):1553-61
103. Xu Y, Tang H, Liu JH, et al. Evaluation of the adjuvant effect of silver nanoparticles both in vitro and in vivo. Toxicol Lett 2013;219(1):42-8
104. Korani M, Rezayat SM, Gilani K, et al. Acute and subchronic dermal toxicity of nanosilver in guinea pig. Int J Nanomedicine 2011;6:855-62
105. Liu W, Wu Y, Wang C, et al. Impact of silver nanoparticles on human cells: effect of particle size. Nanotoxicology 2010;4(3):319-30
106. Park MV, Neigh AM, Vermeulen JP, et al. The effect of particle size on the cytotoxicity, inflammation, developmental toxicity and genotoxicity of silver nanoparticles. Biomaterials 2011;32(36):9810-17
107. Allahverdiyev AM, Abamor ES, Bagirova M, et al. Antileishmanial effect of silver nanoparticles and their enhanced antiparasitic activity under ultraviolet light. Int J Nanomedicine 2011;6:2705-14
108. Allahverdiyev AM, Abamor ES, Bagirova M, Rafailovich M. Antimicrobial effects of TiO(2) and Ag (2)O nanoparticles against drug-resistant bacteria and leishmania parasites. Future Microbiol 2011;6(8):933-40
109. Nilforoushzadeh MA, Shirani-Bidabadi LA, Zolfaghari-Baghbaderani A, et al. Topical effectiveness of different concentrations of nanosilver solution on Leishmania major lesions in Balb/c mice. J Vector Borne Dis 2012;49(4):249-53
110. Larese FF, D'Agostin F, Crosera M, et al. Human skin penetration of silver nanoparticles through intact and damaged skin. Toxicology 2009;255(1-2):33-7
111. Rigo C, Ferroni L, Tocco I, et al. Active silver nanoparticles for wound healing. Int J Mol Sci 2013;14(3):4817-40
112. Allahverdiyev AM, Kon KV, Abamor ES, et al. Coping with antibiotic resistance: combining nanoparticles with antibiotics and other antimicrobial agents. Expert Rev Anti Infect Ther 2011;9(11):1035-52
113. Fayaz AM, Balaji K, Girilal M, et al. Biogenic synthesis of silver nanoparticles and their synergistic effect with antibiotics: a study against gram-positive and gram-negative bacteria. Nanomedicine 2010;6(1):103-9
114. Lee Y, Baron ED. Photodynamic therapy: current evidence and applications in dermatology. Semin Cutan Med Surg 2011;30(4):199-209
115. Kharkwal GB, Sharma SK, Huang YY, et al. Photodynamic therapy for infections: clinical applications. Lasers Surg Med 2011;43(7):755-67
116. Baptista MS, Wainwright M. Photodynamic antimicrobial chemotherapy (PACT) for the treatment of malaria, leishmaniasis and trypanosomiasis. Braz J Med Biol Res 2011;44(1):1-10
117. Song D, Lindoso JA, Oyafuso LK, et al. Photodynamic therapy using methylene blue to treat cutaneous leishmaniasis. Photomed Laser Surg 2011;29(10):711-15
118. Harris F, Pierpoint L. Photodynamic therapy based on 5-aminolevulinic acid and its use as an antimicrobial agent. Med Res Rev 2012;32(6):1292-327
119. Donnelly RF, McCarron PA, Woolfson AD. Drug delivery of aminolevulinic acid from topical formulations intended for photodynamic therapy. Photochem Photobiol 2005;81(4):750-67
120. Wainwright M, Baptista MS. The application of photosensitisers to tropical pathogens in the blood supply. Photodiagnosis Photodyn Ther 2011;8(3):240-8
121. Genina EA, Bashkatov AN, Chikina EE, Tuchin VV. [Diffusion of methylene blue in the human maxillary sinus mucosa]. Biofizika 2007;52(6):1104-11
122. Sharma SK, Dai T, Kharkwal GB, et al. Drug discovery of antimicrobial photosensitizers using animal models. Curr Pharm Des 2011;17(13):1303-19
123. Chatterjee DK, Fong LS, Zhang Y. Nanoparticles in photodynamic therapy: an emerging paradigm. Adv Drug Deliv Rev 2008;60(15):1627-37
124. Fang YP, Wu PC, Tsai YH, Huang YB. Physicochemical and safety evaluation of 5-aminolevulinic acid in novel liposomes as carrier for skin delivery. J Liposome Res 2008;18(1):31-45
125. Akilov OE, Kosaka S, O'Riordan K, Hasan T. Parasiticidal effect of deltaaminolevulinic acid-based photodynamic therapy for cutaneous leishmaniasis is indirect and mediated through the killing of the host cells. Exp Dermatol 2007;16(8):651-60
126. Kosaka S, Akilov OE, O'Riordan K, Hasan T. A mechanistic study of deltaaminolevulinic acid-based photodynamic therapy for cutaneous leishmaniasis. J Invest Dermatol 2007;127(6):1546-9
127. Dutta S, Ongarora BG, Li H, et al. Intracellular targeting specificity of novel phthalocyanines assessed in a hostparasite model for developing potential photodynamic medicine. PLoS One 2011;6(6):e20786
128. Akilov OE, Kosaka S, O'Riordan K, et al. The role of photosensitizer molecular charge and structure on the efficacy of photodynamic therapy against Leishmania parasites. Chem Biol 2006;13(8):839-47
129. Montanari J, Maidana C, Esteva MI, et al. Sunlight triggered photodynamic ultradeformable liposomes against Leishmania braziliensis are also leishmanicidal in the dark. J Control Release 2010;147(3):368-76
130. Hernandez IP, Montanari J, Valdivieso W, et al. In vitro phototoxicity of ultradeformable liposomes containing chloroaluminum phthalocyanine against New World Leishmania species. J Photochem Photobiol B 2012;117:157-63
131. de Melo LS, Gomes AS, Saska S, et al. Singlet oxygen generation enhanced by silver-pectin nanoparticles. J Fluoresc 2012;22(6):1633-8
132. Dalton JE, Kaye PM. Immunomodulators: use in combined therapy against leishmaniasis. Expert Rev Anti Infect Ther 2010;8(7):739-42
133. El-On J. Current status and perspectives of the immunotherapy of leishmaniasis. Isr Med Assoc J 2009;11(10):623-8
134. Saha P, Mukhopadhyay D, Chatterjee M. Immunomodulation by chemotherapeutic agents against Leishmaniasis. Int Immunopharmacol 2011;11(11):1668-79
135. Labro MT. Immunomodulatory effects of antimicrobial agents. Part II: antiparasitic and antifungal agents. Expert Rev Anti Infect Ther 2012;10(3):341-57
136. Arevalo I, Ward B, Miller R, et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis 2001;33(11):1847-51
137. El-On J, Bazarsky E, Sneir R. Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator Imiquimod. Exp Parasitol 2007;116(2):156-62
138. Khalili G, Dobakhti F, Mahmoudzadeh-Niknam H, et al. Immunotherapy with Imiquimod increases the efficacy of Glucantime therapy of Leishmania major infection. Iran J Immunol 2011;8(1):45-51
139. Hussell T. Immune modulatory strategies: a playground with a swing and a seesaw. Expert Rev Anti Infect Ther 2012;10(3):249-51
140. Hartley MA, Kohl K, Ronet C, Fasel N. The therapeutic potential of immune cross-talk in leishmaniasis. Clin Microbiol Infect 2013;19(2):119-30
141. Machado PR, Lessa H, Lessa M, et al. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin Infect Dis 2007;44(6):788-93
142. Rethi B, Eidsmo L. FasL and TRAIL signaling in the skin during cutaneous leishmaniasis - implications for tissue immunopathology and infectious control. Front Immunol 2012;3:163
143. Tasew G, Nylen S, Lieke T, et al. Systemic FasL and TRAIL neutralisation reduce leishmaniasis induced skin ulceration. PLoS Negl Trop Dis 2010;4(10):e844
144. Almeida RP, Brito J, Machado PL, et al. Successful treatment of refractory cutaneous leishmaniasis with GM-CSF and antimonials. Am J Trop Med Hyg 2005;73(1):79-81
145. Dai T, Tanaka M, Huang YY, Hamblin MR. Chitosan preparations for wounds and burns: antimicrobial and wound-healing effects. Expert Rev Anti Infect Ther 2011;9(7):857-79
146. Lonez C, Vandenbranden M, Ruysschaert JM. Cationic lipids activate intracellular signaling pathways. Adv Drug Deliv Rev 2012;64(15):1749-58
147. Chen H, Li P, Yin Y, et al. The promotion of type 1 T helper cell responses to cationic polymers in vivo via toll-like receptor-4 mediated IL-12 secretion. Biomaterials 2010;31(32):8172-80
148. Reinhard K, Huber M, Lohoff M, Visekruna A. The role of NF-kappaB activation during protection against Leishmania infection. Int J Med Microbiol 2012;302(4-5):230-5
149. Lima-Junior DS, Costa DL, Carregaro V, et al. Inflammasome-derived IL-1beta production induces nitric oxide-mediated resistance to Leishmania. Nat Med 2013;19(7):909-15
150. Jaafari MR, Bavarsad N, Bazzaz BS, et al. Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible BALB/c mice. Antimicrob Agents Chemother 2009;53(6):2259-65
151. Frankenburg S, Glick D, Klaus S, Barenholz Y. Efficacious topical treatment for murine cutaneous leishmaniasis with ethanolic formulations of amphotericin B. Antimicrob Agents Chemother 1998;42(12):3092-6
152. Schmidt-Ott R, Klenner T, Overath P, Aebischer T. Topical treatment with hexadecylphosphocholine (Miltex) efficiently reduces parasite burden in experimental cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1999;93(1):85-90
153. Peloi LS, Biondo CE, Kimura E, et al. Photodynamic therapy for American cutaneous leishmaniasis: the efficacy of methylene blue in hamsters experimentally infected with Leishmania (Leishmania) amazonensis. Exp Parasitol 2011;128(4):353-6
154. Rocha MN, Correa CM, Melo MN, et al. An alternative in vitro drug screening test using Leishmania amazonensis transfected with red fluorescent protein. Diagn Microbiol Infect Dis 2013;75(3):282-91
155. Shakya N, Sane SA, Gupta S. Antileishmanial efficacy of fluconazole and miltefosine in combination with an immunomodulator - picroliv. Parasitol Res 2011;108(4):793-800
156. Seifert K, Escobar P, Croft SL. In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent. J Antimicrob Chemother 2010;65(3):508-11
157. Seifert K, Munday J, Syeda T, Croft SL. In vitro interactions between sitamaquine and amphotericin B, sodium stibogluconate, miltefosine, paromomycin and pentamidine against Leishmania donovani. J Antimicrob Chemother 2011;66(4):850-4
158. Reimao JQ, Colombo FA, Pereira-Chioccola VL, Tempone AG. Effectiveness of liposomal buparvaquone in an experimental hamster model of Leishmania (L.) infantum chagasi. Exp Parasitol 2012;130(3):195-9
159. Hart DT, Lauwers WJ, Willemsens G, et al. Perturbation of sterol biosynthesis by itraconazole and ketoconazole in Leishmania mexicana mexicana infected macrophages. Mol Biochem Parasitol 1989;33(2):123-34
160. Suryawanshi SN, Kumar S, Tiwari A, et al. Synthesis and biological evaluation of a novel series of aryl S,N-ketene acetals as antileishmanial agents. Bioorg Med Chem Lett 2013;23(13):3979-82